Exon-16-Skipping Erbb2 (Erbb2 Delta Ex16) As A Novel Resistance Mechanism Against Egfr Tyrosine Kinase Inhibitors In Non-Small Cell Lung Cancer (Nsclc).

9528Background: In addition to ERBB2 amplification/protein overexpression, activating ERBB2 alterations have been increasingly discovered in diverse human cancers with varying incidence. ERBB2ΔEx16...